Insider transaction details
Allogene Therapeutics NASDAQ:ALLO disclosed in a Form 4 filing that Zachary Roberts, the company’s Executive Vice President of Research and Development, sold 35,700 shares of common stock on February 2, 2026. The sale generated approximately $63,189 and was executed at prices ranging from $1.71 to $1.87, near the reported trading price of $1.80.
Concurrent compensation awards
The filing also shows Roberts acquired 718,763 shares via stock options with an exercise price of $1.87. Those options begin vesting on February 2, 2027. In addition, Roberts was granted 203,307 restricted stock units (RSUs) that vest in four equal annual installments beginning February 2, 2026.
Balance sheet and valuation notes
The clinical-stage biotech is reported to have more cash than debt and a current ratio of 8.19, indicating a sizeable short-term liquidity cushion on the balance sheet. The company is described as having an enterprise valuation of roughly $404 million. InvestingPro Fair Value metrics cited in the filing indicate Allogene appears undervalued, and the stock posted a 13% return over the prior week.
Operational and market developments
Allogene’s third-quarter 2025 results exceeded analyst expectations, with earnings per share of -$0.19 versus an estimated -$0.22, representing a positive surprise of 13.64% relative to consensus. The company also received a favorable arbitration ruling that reaffirmed its rights over the cancer therapy cemacabtagene ansegedleucel, a decision described as clearing the way for full global commercialization rights.
Analyst coverage and clinical progress
UBS has initiated coverage on Allogene with a Buy rating and established a price target of $8.00, citing the company’s prospects in developing so-called "off-the-shelf" CAR-T therapies for cancer and autoimmune diseases. Separately, Citizens upgraded Allogene to Market Outperform, pointing to clinical data that reported a 42% overall complete response rate for the company’s cell therapy. Management has announced key clinical milestones targeted for 2026, which the company says may be transformative for its allogeneic CAR T platform and for efforts to deliver therapies at scale in real-world settings.
Research resources and investor guidance
InvestingPro notes it has identified 10 additional investment tips for Allogene Therapeutics and references a Pro Research Report that is part of its in-depth coverage of over 1,400 U.S. equities. The firm’s metrics and analyses are highlighted alongside the corporate disclosures noted above.
Summary
Zachary Roberts sold 35,700 Allogene shares on February 2, 2026 for about $63,189 while receiving large option and RSU awards that vest over multi-year schedules. The company is characterized as having strong short-term liquidity and a market valuation near $404 million. Recent operational items include a Q3 2025 earnings beat, an arbitration ruling securing commercialization rights for a cancer therapy, initiation of coverage by UBS with a Buy rating and an $8.00 target, and an upgrade from Citizens based on clinical response rates. InvestingPro flags the stock as appearing undervalued and lists additional research resources for investors.
Key points
- Insider activity: EVP Zachary Roberts sold 35,700 shares (Feb. 2, 2026) for ~ $63,189, at $1.71 to $1.87 per share, while receiving 718,763 option shares (exercise price $1.87) and 203,307 RSUs with staggered vesting.
- Financial position and market view: Company reported a current ratio of 8.19, more cash than debt, an approximate valuation of $404 million, and InvestingPro’s Fair Value metrics indicate it appears undervalued; stock returned 13% over the past week.
- Operational catalysts: Q3 2025 EPS of -$0.19 beat estimates of -$0.22 (13.64% surprise); arbitration affirmed rights to cemacabtagene ansegedleucel; UBS initiated Buy coverage with an $8.00 target; Citizens upgraded to Market Outperform citing a 42% complete response rate.
Risks and uncertainties
- Clinical outcomes and milestones - The company has flagged key clinical milestones for 2026 described as potentially transformative; the realization and timing of those milestones remain material to future progress.
- Execution and commercialization - While an arbitration ruling reaffirmed commercialization rights for cemacabtagene ansegedleucel, successfully converting legal rights into global commercial execution is a separate, operational challenge.
- Insider transactions - The sale of shares by an executive, even alongside new option and RSU awards, is a notable insider transaction that investors may consider when assessing insider ownership and managerial compensation alignment.
Sectors impacted
- Biotechnology - clinical development, valuation and commercialization dynamics.
- Healthcare - therapeutic development and market access for cell therapies.
- Capital markets - analyst coverage, valuation metrics, and investor liquidity considerations.